The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Raghav Sundar
Stock and Other Ownership Interests - Teladoc
Honoraria - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; DKSH; Ipsen; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/Astra Zeneca; DKSH; Eisai; GlaxoSmithKline; Pierre Fabre; Sanofi; Tavotek BioTherapeutics
Research Funding - CytoMed (Inst); MSD (Inst); Natera (Inst); Paxman (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent (pending): Method Of Predicting For Benefit From Immune Checkpoint Inhibition Therapy; Inventor on patent (pending): Portable Limb Compression System; Inventor on patent (pending): Wearable Limb Wraps for Temperature-Controlled Therapy
Travel, Accommodations, Expenses - AstraZeneca; CytoMed Therapeutics; DKSH; Ipsen; Taiho Pharmaceutical
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Yukinori Kurokawa
Honoraria - Daiichi Sankyo; Johnson & Johnson; Kaken Pharmaceutical; Lilly; MC Medical; Medtronic; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Jian Li
No Relationships to Disclose
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masaaki Iwatsuki
No Relationships to Disclose
 
Jen-Shi Chen
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Janssen; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; Senhwa Biosciences; TTY Biopharm
 
Chueh-Chuan Yen
Consulting or Advisory Role - Full Hope Biomedical
Research Funding - Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Deciphera (Inst); Rain Therapeutics (Inst); Taiho Pharmaceutical (Inst)
 
John Raymond Zalcberg
Leadership - ICON Group; Lipotek
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; CSL Limited; CSL Limited; Frequency Therapeutics; Gilead Sciences; Korro; Moderna Therapeutics; Novavax; Opthea; Orphazyme; UniQure
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Deciphera; FivePHusion; Genor BioPharma; Merck Sharp & Dohme; NOUS Group; Novotech; Oncology Republic; Revolution Medicines; Specialised Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst); Servier (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - ICON Group; MSD Oncology; Praxis Therapeutics
 
Amitesh Chandra Roy
Honoraria - BeiGene; Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Medison; MSD Oncology; Roche
Research Funding - Merck Serono (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
 
Li-Tzong Chen
Leadership - ScinoPharm
Honoraria - ACT Genomics; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SyncoreBio; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CStone Pharmaceuticals; Ipsen; Lilly; MSD; Ono Pharmaceutical; Onward Therapeutics; Taivex Therapeutics; TTY Biopharm
Research Funding - ACT Genomics (Inst); Celgene (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Polaris (Inst); SyncoreBio (Inst); TTY Biopharm (Inst)
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan
 
Toshirou Nishida
Honoraria - Eisai; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Taiho Pharmaceutical
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - A2 Healthcare; A2 Healthcare; Boehringer Ingelheim; Chugai Pharma; Gilead Sciences; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; NanoCarrier; Noil-Immune Biotech; Noil-Immune Biotech; Oncolys BioPharma; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)